Evidence map›Paper›PMID 41206747›Full record

ArticleNeuro-oncology2026

Assessment of molecular tools in pediatric, adolescent, and young adult meningioma highlights the need for lifespan precision in neuro-oncology.

Leeor S Yefet, Alexander P Landry, Justin Z Wang, Jeff Liu, Vikas Patil, Chloe Gui, Andrew Ajisebutu, Yosef Ellenbogen, Yasin Mamatjan, Rebecca Yakubov and 23 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. "Updates on diagnostic and prognostic molecular biomarkers of CNS tumors".Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Leeor S YefetDivision of Neurosurgery, Department of Surgery, University of Toronto, Toronto, ON, Canada (L.S.Y., A.P.L., J.Z.W., C.G., A.A., Y.E., F.N., G.Z.).
Alexander P LandryDivision of Neurosurgery, Department of Surgery, University of Toronto, Toronto, ON, Canada (L.S.Y., A.P.L., J.Z.W., C.G., A.A., Y.E., F.N., G.Z.).
Justin Z WangDivision of Neurosurgery, Department of Surgery, University of Toronto, Toronto, ON, Canada (L.S.Y., A.P.L., J.Z.W., C.G., A.A., Y.E., F.N., G.Z.).
Jeff LiuPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada (L.S.Y., A.P.L., J.Z.W., J.L., V.P., C.G., A.A., Y.E., R.Y., R.K, P.P., Q.W., S.M., S.B., F.N, G.Z.).
Vikas PatilPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada (L.S.Y., A.P.L., J.Z.W., J.L., V.P., C.G., A.A., Y.E., R.Y., R.K, P.P., Q.W., S.M., S.B., F.N, G.Z.).
Chloe GuiDivision of Neurosurgery, Department of Surgery, University of Toronto, Toronto, ON, Canada (L.S.Y., A.P.L., J.Z.W., C.G., A.A., Y.E., F.N., G.Z.).ORCID 0000-0002-6685-1970
Andrew AjisebutuDivision of Neurosurgery, Department of Surgery, University of Toronto, Toronto, ON, Canada (L.S.Y., A.P.L., J.Z.W., C.G., A.A., Y.E., F.N., G.Z.).
Yosef EllenbogenDivision of Neurosurgery, Department of Surgery, University of Toronto, Toronto, ON, Canada (L.S.Y., A.P.L., J.Z.W., C.G., A.A., Y.E., F.N., G.Z.).ORCID 0000-0003-1390-1361
Yasin MamatjanMacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, ON, Canada (L.S.Y., A.P.L., J.Z.W., J.L., V.P., C.G., A.A., Y.E., Y.M., R.Y., R.K, P.P., Q.W., S.M., S.B., F.N, G.Z.).ORCID 0000-0002-8807-2927
Rebecca YakubovPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada (L.S.Y., A.P.L., J.Z.W., J.L., V.P., C.G., A.A., Y.E., R.Y., R.K, P.P., Q.W., S.M., S.B., F.N, G.Z.).
Ramneet KalotiPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada (L.S.Y., A.P.L., J.Z.W., J.L., V.P., C.G., A.A., Y.E., R.Y., R.K, P.P., Q.W., S.M., S.B., F.N, G.Z.).
Phooja PersaudPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada (L.S.Y., A.P.L., J.Z.W., J.L., V.P., C.G., A.A., Y.E., R.Y., R.K, P.P., Q.W., S.M., S.B., F.N, G.Z.).
Qingxia WeiPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada (L.S.Y., A.P.L., J.Z.W., J.L., V.P., C.G., A.A., Y.E., R.Y., R.K, P.P., Q.W., S.M., S.B., F.N, G.Z.).
Olivia SinghDepartment of Neurologic Surgery, Mayo Clinic, Rochester, MN, USA (L.S.Y., O.S., G.Z.).
Sheila MansouriPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada (L.S.Y., A.P.L., J.Z.W., J.L., V.P., C.G., A.A., Y.E., R.Y., R.K, P.P., Q.W., S.M., S.B., F.N, G.Z.).
Severa BundaPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada (L.S.Y., A.P.L., J.Z.W., J.L., V.P., C.G., A.A., Y.E., R.Y., R.K, P.P., Q.W., S.M., S.B., F.N, G.Z.).
Aaron A Cohen-GadolDepartment of Neurological Surgery, Keck School of Medicine, USC, Los Angeles, CA, USA (A.A.C.-G.).
Ghazaleh TabatabaiDepartment of Neurology and Interdisciplinary Neuro-Oncology, Center for Neuro-Oncology, Comprehensive Cancer Center, Hertie Institute for Clinical Brain Research, Eberhard Karls University Tübingen, Tübingen, Germany (G.T.).
Marcos TatagibaDepartment of Neurosurgery, Center for Neuro-Oncology, Comprehensive Cancer Center, Eberhard Karls University Tübingen, Tübingen, Germany (M.T., F.B.).ORCID 0000-0002-1627-9937
Felix BehlingDepartment of Neurosurgery, Center for Neuro-Oncology, Comprehensive Cancer Center, Eberhard Karls University Tübingen, Tübingen, Germany (M.T., F.B.).
Jill S Barnholtz-SloanCenter for Biomedical Informatics & Information Technology (CBIIT), National Cancer Institute, Bethesda, MD, USA (J.S.B.-S.).ORCID 0000-0001-6190-9304
Andrew E SloanDepartment of Neurological Surgery & Piedmont, Brain Tumor Center, Atlanta, GA, USA (A.E.S.).
Silky ChotaiDepartment of Neurosurgery, Vanderbilt University Medical Center, Nashville, TN, USA (S.C., L.B.C.).
Lola B ChamblessDepartment of Neurosurgery, Vanderbilt University Medical Center, Nashville, TN, USA (S.C., L.B.C.).
Alireza MansouriDepartment of Neurosurgery, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA (A.M.).
Sameer AgnihotriDepartment of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, USA (S.A.).
Serge MakarenkoDivision of Neurosurgery, University of British Columbia, Vancouver, BC, Canada (S.M., S.Y.).
Stephen YipDivision of Neurosurgery, University of British Columbia, Vancouver, BC, Canada (S.M., S.Y.).
Derek S TsangRadiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON, Canada (D.S.T.).
Kenneth AldapeCenter for Cancer Research, National Cancer Institute, Bethesda, MD, USA (K.A.).ORCID 0000-0001-5119-7550
Andrew GaoDivision of Laboratory Medicine and Pathobiology, University Health Network, Toronto, ON, Canada (A.G.).
Farshad NassiriDivision of Neurosurgery, Department of Surgery, University of Toronto, Toronto, ON, Canada (L.S.Y., A.P.L., J.Z.W., C.G., A.A., Y.E., F.N., G.Z.).
Gelareh ZadehDivision of Neurosurgery, Department of Surgery, University of Toronto, Toronto, ON, Canada (L.S.Y., A.P.L., J.Z.W., C.G., A.A., Y.E., F.N., G.Z.).

Funding

Canadian Institutes of Health Research and Brain Tumour Charity
6 · The paper itself

Abstract

backgroundAdolescent and young adult (AYA) patients remain underrepresented in neuro-oncology research. Despite being the second most common primary brain tumor in this population, meningiomas have not been studied using age-specific molecular analyses. DNA methylation-based classification and prognostic tools have transformed meningioma care. This study aimed to evaluate the performance of these tools across age groups.

methodsWe analyzed 1,568 meningiomas with DNA methylation and clinical data, including 18 pediatric patients (<15 years), 195 AYA patients (15-39 years), and 1,355 adult patients (>39 years). Pediatric and AYA (P/AYA) tumors were combined and compared with adult tumors. The performance of established molecular classifiers and recurrence predictors, as well as differences in chromosomal copy number alterations were compared across age groups.

resultsWhile histologic grading was comparable between cohorts, P/AYA tumors displayed significantly fewer aggressive molecular groups and lower frequencies of chromosomal arm losses, including 1p, 6q, and 14q. The adult-trained recurrence predictor failed in the P/AYA population (AUC 0.57), despite similar score distributions. Retraining the model on an age-specific cohort using an identical analytic framework improved performance (AUC 0.79) and enabled effective stratification of progression-free survival (P = 0.00054). Importantly, 1p loss retained prognostic significance within the P/AYA group, supporting its clinical utility.

conclusionsMolecular tools developed in adult-dominant cohorts do not generalize to younger patients due to both biological divergence and exclusion from model development. These findings underscore the need for age-specific molecular frameworks and highlight the imperative of including P/AYA populations in precision neuro-oncology research to ensure lifespan-equitable care.

Indexed as

Biomarkers, TumorDNA MethylationMeningeal NeoplasmsMeningiomaNeoplasm Recurrence, LocalAdolescentAdultChildDNA Copy Number VariationsFemaleFollow-Up StudiesHumansMalePrognosisSurvival RateYoung AdultBiomarkers, Tumoradolescent and young adult (AYA)DNA methylationmeningiomaneuro-oncologypediatric

Identifiers

PMID41206747
PMCPMC13070492

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.